This fact, combined with the observed in vivo anti-SARS-CoV-2 activity, suggests further testing the anti-viral activity of PIXN or other HS inhibitors in clinical trials for patients with severe COVID-19 symptoms. This evidence concerns the gene MAP3K14 and COVID-19.